Cambridge, UK-based biotech Bicycle Therapeutics, which is pioneering a new and differentiated class of therapeutics based on ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...
Travis Thompson appointed chief financial officer; to succeed Alethia Young Michael Method, M.D., MPH, MBA promoted to chief medical officer; to succeed Eric Westin, M.D. Michael Skynner, Ph.D.
Morning Overview on MSN
A 100-year-old chemistry rule just got shattered twice by new science
Chemistry students are taught that some molecular shapes are so strained they simply cannot exist. For about 100 years, one ...
Researchers synthesized weird molecules that exist in three dimensions, breaking Bredt's rule and helping to develop future ...
Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Emerging radiopharmaceuticals ...
ABSTRACT: A photochemical [2+2] cycloaddition between cyclopentene-1-one and 1,1-dimethoxyethylene was effectively utilized to synthesize a key bicyclic intermediate in the preparation of tricyclic ...
A photochemical [2+2] cycloaddition between cyclopentene-1-one and 1,1-dimethoxyethylene was effectively utilized to synthesize a key bicyclic intermediate in the preparation of tricyclic ...
Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens ...
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.5c01051.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results